Logicbio therapeutics, inc. (LOGC)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17
REVENUE
Total revenue

1,021

-

-

-

-

-

-

-

-

-

OPERATING EXPENSES
Research and development

7,173

8,378

8,858

7,934

5,486

4,966

2,432

2,226

1,455

580

General and administrative

3,192

3,054

2,175

2,524

2,632

2,411

2,119

1,416

918

470

Total operating expenses

10,365

11,432

11,033

10,458

8,118

7,377

4,551

3,642

2,373

1,050

LOSS FROM OPERATIONS

-9,344

-11,432

-11,033

-10,458

-8,118

-7,377

-4,551

-3,642

-2,373

-1,050

OTHER INCOME (EXPENSE), NET:
Interest income

167

257

389

411

443

366

75

60

68

-2

Interest expense

272

-

271

-

-

-

1

-

-

-

Other expense, net

-6

-

-3

-1

-

-1

-154

-7

3

37

Total other income (expense), net

-111

-33

115

410

443

364

-80

53

71

35

Loss before income taxes

-9,455

-11,465

-10,918

-10,048

-7,675

-7,013

-4,631

-3,589

-2,302

-1,015

Income tax provision

-

0

0

0

22

48

38

-2

2

29

Net loss

-9,455

-11,465

-10,918

-10,048

-7,697

-7,061

-4,669

-3,587

-2,304

-1,044

Net loss attributable to common stockholders—basic and diluted (Note 10)

-

-

-10,918

-10,048

-

-

-8,621

-8,217

-4,907

-2,306

Net loss per share—basic and diluted

-0.41

-0.51

-0.48

-0.45

-0.34

7.93

-4.03

-4.19

-2.75

-1.55

Weighted-average common stock outstanding—basic and diluted

23,175

22,941

22,677

22,479

22,313

17,318

2,138

1,962

1,787

1,483